A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

BACKGROUND: This phase I study assessed the maximum tolerated dose, dose-limiting toxicity (DLT) and pharmacokinetics of belinostat with carboplatin and paclitaxel and the anti-tumour activity of the combination in solid tumours. METHODS: Cohorts of three to six patients were treated with escalating...

Descripción completa

Detalles Bibliográficos
Autores principales: Lassen, U, Molife, L R, Sorensen, M, Engelholm, S-A, Vidal, L, Sinha, R, Penson, R T, Buhl-Jensen, P, Crowley, E, Tjornelund, J, Knoblauch, P, de Bono, J S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905291/
https://www.ncbi.nlm.nih.gov/pubmed/20588278
http://dx.doi.org/10.1038/sj.bjc.6605726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905291/
https://www.ncbi.nlm.nih.gov/pubmed/20588278
http://dx.doi.org/10.1038/sj.bjc.6605726

Ejemplares similares